Questions

1022. Deputy Ken O'Flynn asked the Minister for Health whether the absence of a standardised definition of medical necessity in surgical care creates a governance risk in relation to waiting lists, theatre access, and resource allocation; and if she will make a statement on the matter. [32585/26]

1023. Deputy Ken O'Flynn asked the Minister for Health whether she will request the HSE to prepare options for improved reporting on theatre-capacity allocation, including reporting by specialty, urgency, elective status, and clinical priority; and if she will make a statement on the matter. [32586/26]

1042. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 953 of 24 March 2026, whether the national guideline for the diagnosis and management of lipoedema referenced will include provision for surgical intervention; if not, the policy basis for excluding surgical treatment from the national care pathway; and whether patients will be supported to access surgical care where clinical…

1043. Deputy Ken O'Flynn asked the Minister for Health the estimated number of persons living with lipoedema in the State; the projected demand for services under the proposed national care pathway; and the current and planned service capacity within the public health system to meet this demand. [32621/26]

1044. Deputy Ken O'Flynn asked the Minister for Health the total budget allocation assigned to the development and implementation of the national lipoedema care pathway; the costings associated with clinical services, education programmes and patient supports; and whether dedicated funding has been ring-fenced for this purpose. [32622/26]

1045. Deputy Ken O'Flynn asked the Minister for Health the governance framework underpinning the national lipoedema care pathway, including the identity and role of the clinical lead, reporting arrangements to the Department, and whether a formal audit, evaluation, or outcomes monitoring mechanism will be established. [32623/26]

1047. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 953 of 24 March 2026, the exact publication date for the national lipoedema guideline referenced in; the reasons for any delay beyond the second quarter of 2026; and whether a full implementation plan will be published alongside the guideline [32625/26]

1048. Deputy Ken O'Flynn asked the Minister for Health whether the national lipoedema care pathway will include defined referral criteria, multidisciplinary team structures, and standardised diagnostic protocols across all regions; and if she will outline these components. [32626/26]

1049. Deputy Ken O'Flynn asked the Minister for Health the expected waiting times for assessment and treatment under the proposed lipoedema care pathway; and whether waiting list data will be collected and published on a regular basis. [32627/26]

1050. Deputy Ken O'Flynn asked the Minister for Health whether the lipoedema care pathway will be delivered on a national basis with equal access across all Community Healthcare Organisation areas; and if she will provide a breakdown of planned service locations. [32628/26]

1051. Deputy Ken O'Flynn asked the Minister for Health the clinical evidence and policy analysis used to inform the scope of the national lipoedema guideline; and whether international best practice, including surgical treatment options, was considered in its development. [32629/26]

1077. Deputy Ken O'Flynn asked the Minister for Health the extent to which the “potential risk of human error” in partially manual data submission processes has been quantified; whether any error rates have been identified; and the corrective measures in place to mitigate such risks. [29884/26]

241. Deputy Ken O'Flynn asked the Minister for Health whether any interim access schemes, compassionate use programmes, or early access pathways are currently available in the State for patients with Friedreich’s ataxia; and whether consideration is being given to enabling access to skyclarys pending a full reimbursement decision. [29080/26]

245. Deputy Ken O'Flynn asked the Minister for Health whether the current national rare disease strategy provides for expedited access pathways to disease-modifying therapies; and whether any review of this policy framework is underway. [29084/26]

757. Deputy Ken O'Flynn asked the Minister for Health the average cost per individual procedure funded under the treatment abroad scheme in respect of gender affirmation surgeries in each year from 2020 to 2025; the methodology used to calculate or monitor such costs; and the financial control or value-for-money mechanisms in place to assess these expenditures. [28044/26]

758. Deputy Ken O'Flynn asked the Minister for Health whether any internal or external audits have been conducted on the funding of gender affirmation surgeries under the treatment abroad scheme since 2020; if so, to provide details of the findings, dates, and recommendations; and if not, the reason no such audit has been undertaken. [28045/26]

759. Deputy Ken O'Flynn asked the Minister for Health the clinical outcome measures, follow-up requirements, or post-operative monitoring arrangements are in place for patients who undergo gender affirmation surgery funded under the treatment abroad scheme; and how such outcomes are recorded and evaluated at a national level. [28046/26]

760. Deputy Ken O'Flynn asked the Minister for Health the reason the treatment abroad scheme does not record or maintain data on the type of procedures funded under gender affirmation surgery referrals; whether there are plans to introduce such data collection; and the timeframe for implementation. [28047/26]

761. Deputy Ken O'Flynn asked the Minister for Health the specific clinical and administrative criteria applied when approving applications under the treatment abroad scheme for gender affirmation surgery; whether any refusal thresholds or review mechanisms exist; and the role of multidisciplinary teams in this process. [28048/26]

788. Deputy Ken O'Flynn asked the Minister for Health whether national clinical guidelines or standardised protocols are in place governing follow-up care for patients returning to the State after receiving procedures funded under the treatment abroad scheme; and if not, whether such guidelines will be developed. [28105/26]

791. Deputy Ken O'Flynn asked the Minister for Health to clarify the apparent discrepancy whereby expenditure was recorded under the treatment abroad scheme for paediatric gender services in 2024 despite no referrals being recorded in that year; and to outline the accounting and reporting methodology used to link expenditure to individual patient referral years. [28108/26]

792. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme records total cost per patient episode, including multi-year treatment costs; and if she will provide the average and total cost per minor referred for gender-related treatment abroad since 2020. [28109/26]

793. Deputy Ken O'Flynn asked the Minister for Health whether clinical outcomes, complications, or follow-up care requirements are recorded for minors referred abroad for gender-related treatment under the treatment abroad scheme; and if so, the mechanisms used to monitor and evaluate these outcomes. [28110/26]

794. Deputy Ken O'Flynn asked the Minister for Health the arrangements are in place within the HSE to provide ongoing clinical care, including psychological and medical follow-up, to minors who have received gender-related treatment abroad under the treatment abroad scheme. [28111/26]

795. Deputy Ken O'Flynn asked the Minister for Health the policy basis upon which referrals of minors for gender-related treatment abroad continue to be authorised in light of changes to paediatric gender services in the United Kingdom following the Cass Review; and whether any review of Irish referral practices has been undertaken. [28112/26]